Skip to main content

Advertisement

SpringerLink
Log in

The clinical significance of MIB-1 labeling index in pituitary adenomas

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Pituitary adenomas are unique in several ways—they are rarely malignant and yet can be invasive of several compartments. Recurrences in tumors with bland histological features that have been radically excised are a reason for frustration faced by endocrinologists and neurosurgeons in treatment of pituitary adenomas. Several attempts have therefore been made to determine the growth potential of pituitary adenomas. The aim of the present study was to define the biological significance of the MIB-1 labelling index (MIB-1 LI) in pituitary adenomas. The study included 159 cases of surgically treated pituitary adenoma seen in a single institution. MIB-1 LI was not found to be related to age or gender. The mean MIB-1 LI for clinically functional adenomas was marginally higher than that for clinically non-functional adenomas. There was a significant difference in the MIB-1 LI for tumors with a maximum diameter of more than 4 cm at a MIB-1 LI of ≥2%, however this difference was not statistically significant at a higher MIB-1 LI cut off value of >3%. The mean MIB-1 LI was significantly higher in tumors causing hydrocephalus and in those with cavernous sinus invasion and not when invasion was defined as invasion by tumor in any direction. We conclude that large pituitary macroadenomas, tumors filling the third ventricle causing hydrocephalus and tumors with true cavernous sinus invasions are more likely to have a higher proliferation index. Close follow up of tumors showing these imaging features would be recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics. Tumors of endocrine organs In: World Health Organization Classification of Tumors Lyon: IARC Press

  2. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202

    Article  CAS  PubMed  Google Scholar 

  3. Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97–126

    Article  CAS  PubMed  Google Scholar 

  4. Farrell WE (2006) Pituitary tumours: findings from whole genome analyses. Endocr Relat Cancer 13:707–716

    Article  CAS  PubMed  Google Scholar 

  5. Pack SD, Qin LX, Pak E et al (2005) Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43:72–82

    Article  CAS  PubMed  Google Scholar 

  6. Szymas J, Schluens K, Liebert W, Petersen I (2002) Genomic instability in pituitary adenomas. Pituitary 5:211–219

    Article  CAS  PubMed  Google Scholar 

  7. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321

    Article  CAS  PubMed  Google Scholar 

  8. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor kdr/flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244

    Article  CAS  PubMed  Google Scholar 

  9. De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouillas J, Fedele M, Fusco A (2009) HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69:1844–1850

    Article  PubMed  Google Scholar 

  10. Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165–186

    Article  CAS  PubMed  Google Scholar 

  11. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A (2002) Loss of expression of gadd45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262–1267

    Article  CAS  PubMed  Google Scholar 

  12. Farrell WE (2005) Epigenetic mechanisms of tumorigenesis. Horm Metab Res 37:361–368

    Article  CAS  PubMed  Google Scholar 

  13. Chatterjee S, May PL, Forster G, Spiller D, Jeffreys RV (1993) Prediction of recurrence in pituitary tumours: a flow cytometric study using in vivo bromodeoxyuridine. Br J Neurosurg 7:165–169

    Article  CAS  PubMed  Google Scholar 

  14. Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE, Weiss MH, Apuzzo ML (1988) Flow cytometric analysis of pituitary tumors correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 62:1556–1560

    Article  CAS  PubMed  Google Scholar 

  15. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 8:160–164

    CAS  PubMed  Google Scholar 

  16. Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753–761

    Article  CAS  PubMed  Google Scholar 

  17. Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl (Wien) 53:60–64

    CAS  Google Scholar 

  18. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25:927–930

    Article  CAS  PubMed  Google Scholar 

  19. Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67:803–806

    Article  CAS  PubMed  Google Scholar 

  20. Lath R, Chacko G, Chandy MJ (2001) Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurol India 49:144–147

    CAS  PubMed  Google Scholar 

  21. Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12

    Article  CAS  PubMed  Google Scholar 

  22. Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1:213–220

    Article  CAS  PubMed  Google Scholar 

  23. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106

    Article  CAS  PubMed  Google Scholar 

  24. Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494

    Article  PubMed  Google Scholar 

  25. Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243

    Article  CAS  PubMed  Google Scholar 

  26. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469

    CAS  PubMed  Google Scholar 

  27. Devaprasath A, Chacko G (2003) Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Neurol India 51:336–340

    CAS  PubMed  Google Scholar 

  28. Yonezawa K, Tamaki N, Kokunai T (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494–500

    Article  CAS  PubMed  Google Scholar 

  29. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time patient age and MIB-1 index. J Neurosurg 98:359–365

    Article  PubMed  Google Scholar 

  30. Losa M (1999) Pituitary tumors in the elderly. Eur J Endocrinol 140:378–380

    Article  CAS  PubMed  Google Scholar 

  31. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313–1318

    Article  CAS  PubMed  Google Scholar 

  32. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107

    Article  CAS  PubMed  Google Scholar 

  33. Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046–1052

    Article  CAS  PubMed  Google Scholar 

  34. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353

    Article  PubMed  Google Scholar 

  35. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Ruggeri A, Peciarolo A (2000) Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody. Tumori 86:229–232

    CAS  PubMed  Google Scholar 

  36. Eda M, Saeki N, Fujimoto N, Sunami K (2002) Demonstration of the optic pathway in large pituitary adenoma on heavily t2 weighted mr images. Br J Neurosurg 16:21–29

    Article  CAS  PubMed  Google Scholar 

  37. Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142:1345–1351

    Article  CAS  Google Scholar 

  38. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–770

    Article  CAS  PubMed  Google Scholar 

  39. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679

    Article  PubMed  Google Scholar 

  40. Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136:37–43

    Article  CAS  Google Scholar 

  41. Bannur U, Chacko G, Chandy MJ (1998) AgNOR count as an index of invasion in pituitary adenoma. Br J Neurosurg 12:582–584

    Article  Google Scholar 

  42. Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P (2004) Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 61:436–445

    Article  PubMed  Google Scholar 

  43. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138:1449–1455

    Article  CAS  Google Scholar 

  44. Saeger W (2005) Pituitary tumors: prognostic indicators. Endocrine 28:57–66

    Article  CAS  PubMed  Google Scholar 

  45. de Aguiar PH, Aires R, Laws ER, Isolan GR, Logullo A, Patil C, Katznelson L (2010) Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res (EPub ahead of print)

  46. Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111:563–571

    Article  PubMed  Google Scholar 

  47. Salehi F, Agur A, Scheithauer BW et al (2009) Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65:429–437 discussion 437

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Neuropathology, Department of Neurological Sciences & Pathology, Christian Medical College, Vellore, 632004, India

    Geeta Chacko

  2. Division of Neurosurgery, Department of Neurological Sciences, Christian Medical College, Vellore, India

    Ari G. Chacko

  3. Department of Laboratory Medicine, St. Michaels Hospital, Toronto, ON, Canada

    Kalman Kovacs

  4. Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

    Bernd W. Scheithauer

  5. Department of Radiology, Christian Medical College, Vellore, India

    Sunithi Mani

  6. Department of Community Health, Christian Medical College, Vellore, India

    J. P. Muliyil

  7. Department of Endocrinology, Christian Medical College, Vellore, India

    M. S. Seshadri

Authors
  1. Geeta Chacko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ari G. Chacko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kalman Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernd W. Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sunithi Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. P. Muliyil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. S. Seshadri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geeta Chacko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chacko, G., Chacko, A.G., Kovacs, K. et al. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13, 337–344 (2010). https://doi.org/10.1007/s11102-010-0242-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-010-0242-7

Keywords

Search

Navigation